Fed. Circ. Doubts 'Ad Hoc' Group Can Revive Amarin Drug IP
A Federal Circuit panel expressed skepticism Friday that a self-described "ad hoc" group that includes Amarin Pharma Inc. shareholders has standing to intervene to challenge a Nevada federal judge's invalidation of...To view the full article, register now.
Already a subscriber? Click here to view full article